219 related articles for article (PubMed ID: 25010770)
1. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.
Ando K; Takahashi F; Kato M; Kaneko N; Doi T; Ohe Y; Koizumi F; Nishio K; Takahashi K
PLoS One; 2014; 9(7):e102436. PubMed ID: 25010770
[TBL] [Abstract][Full Text] [Related]
2. Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation.
Ohira T; Nishio K; Ohe Y; Arioka H; Nishio M; Funayama Y; Ogasawara H; Fukuda M; Yazawa K; Kato H; Saijo N
J Cancer Res Clin Oncol; 1996; 122(12):711-5. PubMed ID: 8954167
[TBL] [Abstract][Full Text] [Related]
3. Brucea javanica oil emulsion alleviates cachexia induced by Lewis lung cancer cells in mice.
Chen C; Wang B
J Drug Target; 2018 Mar; 26(3):222-230. PubMed ID: 28701059
[TBL] [Abstract][Full Text] [Related]
4. Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer.
Sakamoto M; Mikasa K; Majima T; Hamada K; Konishi M; Maeda K; Kita E; Narita N
Chemotherapy; 2001 Dec; 47(6):444-51. PubMed ID: 11786660
[TBL] [Abstract][Full Text] [Related]
5. EXT418, a novel long-acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice.
Kerr HL; Krumm K; Lee II; Anderson B; Christiani A; Strait L; Breckheimer BA; Irwin B; Jiang AS; Rybachok A; Chen A; Caeiro L; Dacek E; Hall DB; Kostyla CH; Hales LM; Soliman TM; Garcia JM
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1337-1348. PubMed ID: 36942661
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
[TBL] [Abstract][Full Text] [Related]
7. [Cytokines in experimental cancer cachexia].
Niu Q; Li T; Liu A
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):382-4. PubMed ID: 11810767
[TBL] [Abstract][Full Text] [Related]
8. Effects of S-pindolol in mouse pancreatic and lung cancer cachexia models.
Springer J; Jové Q; de Lima Junior EA; Ladrón NÁ; López-Soriano FJ; Busquets S; Argiles JM; Marks DL
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1244-1248. PubMed ID: 37130578
[TBL] [Abstract][Full Text] [Related]
9. The concurrent treatment of Scutellaria baicalensis Georgi enhances the therapeutic efficacy of cisplatin but also attenuates chemotherapy-induced cachexia and acute kidney injury.
Huang TH; Wu TH; Guo YH; Li TL; Chan YL; Wu CJ
J Ethnopharmacol; 2019 Oct; 243():112075. PubMed ID: 31291609
[TBL] [Abstract][Full Text] [Related]
10. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
11. Serum IL-35 levels is a new candidate biomarker of cancer-related cachexia in stage IV non-small cell lung cancer.
Li Z; Zhu L; Zheng H; Jiang W; Wang Y; Jiang Z; Xu J
Thorac Cancer; 2022 Mar; 13(5):716-723. PubMed ID: 35142058
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia.
Weber BZC; Agca S; Domaniku A; Bilgic SN; Arabaci DH; Kir S
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1582-1594. PubMed ID: 35373517
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.
Tseng YC; Kulp SK; Lai IL; Hsu EC; He WA; Frankhouser DE; Yan PS; Mo X; Bloomston M; Lesinski GB; Marcucci G; Guttridge DC; Bekaii-Saab T; Chen CS
J Natl Cancer Inst; 2015 Dec; 107(12):djv274. PubMed ID: 26464423
[TBL] [Abstract][Full Text] [Related]
14. Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-κB and activating SIRT1.
Chen C; Ju R; Zhu L; Li J; Chen W; Zhang DC; Ye CY; Guo L
Naunyn Schmiedebergs Arch Pharmacol; 2017 Apr; 390(4):423-433. PubMed ID: 28124088
[TBL] [Abstract][Full Text] [Related]
15. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia.
Ando K; Takahashi F; Motojima S; Nakashima K; Kaneko N; Hoshi K; Takahashi K
J Clin Oncol; 2013 Feb; 31(6):e69-72. PubMed ID: 23129740
[No Abstract] [Full Text] [Related]
16. Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells.
Noguchi-Sasaki M; Sasaki Y; Shimonaka Y; Mori K; Fujimoto-Ouchi K
BMC Cancer; 2016 Apr; 16():270. PubMed ID: 27068103
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Fujimoto-Ouchi K; Onuma E; Shirane M; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):807-15. PubMed ID: 17009035
[TBL] [Abstract][Full Text] [Related]
20. Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.
Sato H; Naito T; Ishida T; Kawakami J
Eur J Clin Pharmacol; 2016 Dec; 72(12):1463-1470. PubMed ID: 27566315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
